
This study zzso analyzed data from zzso patients given zzso cell transplants from zzso related or unrelated donors after conditioning with 2 zzso total body zzso with or without zzso and zzso zzso with zzso zzso and zzso following zzso zzso of zzso patients received donor zzso infusion zzso with a median zzso dose of 1 zzso zzso zzso Their diagnoses included zzso syndrome zzso zzso 10), acute leukemia zzso zzso 10), chronic leukemia zzso zzso zzso multiple myeloma zzso zzso zzso zzso zzso zzso zzso and solid tumors zzso zzso zzso Patients received zzso for persistent disease zzso zzso zzso disease zzso zzso zzso 17), progressive disease zzso zzso zzso low donor zzso with disease zzso zzso zzso or low zzso with disease zzso zzso zzso zzso zzso of the 53 patients zzso are alive with a median follow-up of 30 zzso 5 are in complete zzso zzso 2 are in partial zzso zzso and 10 have stable or progressive zzso Nine of 53 patients zzso developed grades II to IV acute zzso zzso Of 48 patients receiving zzso for treatment of disease, 7 achieved zzso and 5 zzso with an overall response rate of zzso Six of 16 patients who received zzso for zzso had increases in donor zzso leading to sustained zzso whereas 10 eventually rejected their zzso In conclusion, zzso is a potential treatment strategy, with acceptable zzso for patients with persistent, zzso or progressive disease after zzso zzso cell zzso 

